Medires Publishers - Article

Abstract

Lung cancer is a disease associated with significant morbidity and mortality on a global setting. This form of cancer commonly gives raise to metastatic lesions the brain, which can further worsen outcomes. In this focused review, we discuss an overview of lung cancers that metastasize to the brain: known risk factors; means of detection and diagnosis; and options for treatment including a comparison between surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy. These interventions are still being assessed by clinical trials and continue to be modified through evidence-based practice. 

Introduction

Lung cancer is the most common form of malignancy and cause of cancer-related deaths in the world, and the second leading form of cancer-related deaths in the United States.[1-2] Several types of lung cancer exist and may roughly be grouped into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter being broken down further into adenocarcinoma, squamous cell cancer, and large cell carcinoma.[3] Cases of respiratory cancers with metastases involving the brain have been associated with significantly higher levels of both morbidity and mortality.[4-5] An estimated 20% of patients who present with lung cancer will have a brain metastasis at the time of diagnosis, and up to 50% of lung cancer patients will develop brain metastases (BrMs) over the course of their illness.[6-8] The formation of BrMs is a complex, multistep process that involves the spread of cancerous cells from the initial site of neoplastic growth to the eventual colonization of the brain.[9-10] Genetic analyses have linked several driver mutations in the development of BrMs in varying lung malignancies: mutations in tumor suppressor LKB1 and KRAS are predictive of BrMs in NSCLCs;[11] lung adenocarcinomas with mutations in EGFR and ALK, and hyperactivity within the WNT signally pathway have demonstrated higher occurrence of BrMs;[12-14] and upregulation of ANGT4 and PDGFRB genes have been linked with SCLC BrMs.[15]

Central Nervous System Diagnosis

BrMs are often initially detected from imaging as part of a metastatic tumor workup, or following the advent of clinical symptoms; with a definitive diagnosis later being confirmed via biopsy.[16-17] BrMs, particularly with those presenting with neurologic symptoms, are associated with a poorer prognosis.[4-18-19] However, outcomes are greatly improved when metastases are detected earlier, and are thus smaller in size.[4-18] Early detection could allow for use of minimally invasive procedures such as LITT,[20] stereotactic radiosurgery,[21-23] gamma knife surgery,[24] whole brain radiotherapy, or chemotherapy.[23] As such, there is increasing research for the detection of early brain metastases, with a focus on identifying risk factors.  Previous research has identified several risk factors specific for the presence of BrMs in NSCLC: being the female gender; concurrent lymphatic metastases; specific microRNA signatures; a high neutrophil to lymphocyte (NLR) ratio; elevated levels of neurofilament light chain; presence of EGFR driver mutation; and elevated serum levels of CEA, S100B, ProApolipoprotein A1 (apo A-1), Ki-67, VEGF-C, caspace-3, and calcium.[25-37] Sun, et at., have even postulated that ProApolipoprotein A1 and S100B alone may be used for an independent and accurate diagnosis of metastatic brain tumors; which could allow a clinician performing metastatic work ups to administer prophylactic treatments, such as intracranial irradiation.[25] 

Preclinical studies using rodent models have demonstrated early detection of BrMs by employing molecular MRI with contrast agents that highlight tumor vascular factors ALCAM21 and VCAM-1.[38-40] Routine pre-operative and post-operative imaging should also be considered: a study by Yokoi, et al., showed that CT and MRI detected brain metastases in 6.8% and 7.1% of 155 and 177 patients, respectively, during the perioperative period for patients with non-squamous cell lung cancer.[41] Preclinical rodent studies have also indicated that brain metastases can be diagnosed even at micrometastatic stages by screening for urine metabolites; however, these were not specific for lung cancer.[42] The development of machine learning algorithms has also been shown as a promising method of early detection. Machine learning is performed by teaching a machine a dataset with known predictors and outcomes using algorithms. What the machine then “learns” can be used in diagnosis in datasets where the diagnosis is unknown.[43-44] Cho (2021) performed a systematic review and meta-analysis of 12 studies using classical machine learning and deep learning on MRI modalities, revealing pooled 88.7% and 90.1

Imaging Modalities

Several options in terms of imaging modalities are available in the diagnosing of BrMs. Magnetic Resonance Imaging (MRI) is the modality primarily used in the diagnosing and localization of brain tumors in patients with brain lesions, as high level of availability, comparatively high resolution, and excellent capabilities for the characterization of soft tissues are provided by this device; additionally, with specific sequences, supplementary biological information like apoptosis, cell density, or angiogenesis can be measured (diffusion-weighted MRIs or perfusion-weighted MRIs)[48-49] Certain paramagnetic contrast agents (CA) can also reveal impaired blood-brain barriers (BBBs).[50] The downside to the modality is the lack of specificity for neoplastic tissue, which makes it challenging to detect malignancies, monitor cancer progression, or detect potential lesion growth.[51] Additionally, MRI is unable to assess treatment response after surgery, chemotherapy, or radiotherapy nor the quantity of inflammatory, demyelinating, infarction, and ischemia.[48]  A molecular imaging technique called Positron Emission Tomography (PET), which detects emitted photons from radiotracers, is another advanced imaging technique widely used in brain cancer patients. Using PET imaging, metabolic processes, like glucose metabolism and amino acid uptake, can be measured noninvasively and quantitatively.[52] Despite this, PET is unable to distinguish between grey and white matter structural abnormalities. PET is also limited by its lower spatial resolution, and inability to detect rapid changes in brain activity.[53] However, PET does have the advantage of being able to co-register medical images with other imaging methods. In oncology, integrating these two techniques to develop simultaneous multimodal imaging is particularly relevant, as it allows clinicians to assess the tumor microenvironment with the help of several diagnostic biomarkers.[54-55] 

Hybrid PET/MRI scanners enable high-resolution metabolic and anatomical imaging.[53-56] This method combines both the high sensitivity of PET and the high resolution of MRI to provide a comprehensive picture of anatomical details. These coupled PET and MRI examinations may prove to be significantly more advantageous than independent examinations when attempting to understand tumor characteristics and determining whether surgery or radiation therapy would be an more appropriate intervention.[54-57] However, there is no conclusive evidence that PET/MRI is superior to PET/CT in oncology, and hybrid PET/MRI systems typically require longer scanning times and are associated with higher costs when compared to PET/CT systems.[58] Radiopharmaceuticals should be selected based on the characteristics of the tumor being examined. PET tracers like [18F] fluorodeoxyglucose (FDG) are most used because tumor cells exhibit a higher glucose metabolism than healthy tissues[54-59] In cancer cells, [18F] FDG is trapped after crossing the BBB. Beta-emitting 14Cdeoxyglucose (DG) was demonstrated as a BBB crosser in the early 1970s.[60] By the hexokinase system, [18F] FDG is phosphorylated by glucose transporters and transported into cells. As a result, it persists in tissues for a long time since it cannot be metabolized.[61] [18F] FDG has a low specificity and shows a high background uptake by the normal brain despite its widespread use in clinical practice. A PET tracer based on amino acids was developed in response to these limitations.[54-62] It can be demonstrated that these amino acid tracers are elevated in malignant tumors because of unregulated protein synthesis, a symptom of increased cell proliferation.[49] The most common examples are 3'-deoxy-3'-[18F] fluorothymidine ([18F] FLT), 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine ([18F] FDOPA), and [11C] methionine ([11C] MET).[54-59-62-63] 

Treatment

Current treatments for lung cancer patients with BrMs include supportive care, surgical resection, radiotherapies.[64] The integration of palliative care in the management of BrMs should also be considered as it has been shown to greatly improve the quality of life, appetite, and mood; and is correlated with better survival rates, despite less aggressive treatment.[65] Supportive medications, such as steroids and antiseizure drugs, have also demonstrated increased survival rates when coupled with traditional radiotherapies.[6-66-68] 

Surgical Management

The discussion of surgically resecting BrMs is best under- stood by first outlining the distinct subsets of clinical presentations. One subset is when the tumor size is large and causing severe neurologic symptoms, such as mass effect. [69-70] The former subset often falls under the category of necessarily more urgent or emergent in nature, often requiring hastened neurosurgical intervention.[71-72] The mech- anism behind this presentation may be either due to direct pressure on the brain tissue from the tumor itself, or from uncontrolled cerebral edema that secondarily increases intracranial pressure and can lead to acute herniation syndrome. [73] Given that some evidence points to the capacity for brain metastases to cause even more cerebral edema than primary tumors, this may further increase the importance of considering expedited neurosurgical intervention in these patients via resection of the tumor.[74-75]

Another subset of patients who meet criteria for surgical resection are those with a brain metastasis that is not large or causing severe neurologic symptoms, but in patients in which the intracranial disease is limited, systemic disease is controlled, and the patient is functionally independent. [70-76] Furthermore, surgery is often preferred with an extra- cranial metastasis from lung cancer if there is only one single lesion.[77] Given that radiation therapy is a commonly used treatment modality for brain metastases from lung cancer, it is also important to describe when surgery is preferred in these instances. This is often the case with BrMs that arise from a primary lung cancer that is resistant to radiotherapy. [78-79] Surgery for patients comprised in this subset is also often indicated in patients who have had radiation therapy in the past, as this is often necessary to definitively distinguish between radiation-related tissue necrosis and presence of tumor metastasis.[80-82] Lastly, in patients with multiple brain metastases, surgical resection is commonly indicated for the dominant lesion. [83] A summary of the above indications is outlined in Figure.1

Figure 1: Summary of treatment work process for BrMs

Table 1: Summary of known risk factors and pre-clinical studies with early detection of BrMs in lung cancer.

Radiation

Radiotherapies in the treatment of metastatic brain lesions are primarily groups into Stereotactic radiosurgery (SRS), and whole brain radiation therapy (WBRT).[84-85] SRS is a non-invasive form of radiation therapy that uses concentrated, multifocal beams of radiation to destroy tissues.[84-86] There are multiple radiation delivery methods of SRS: Gamma Knife, Linear accelerator (LINAC), and Proton beam therapy. Gamma knife surgery uses gamma radiation in a very small operating field, while LINAC uses x-ray radiation with greater operating flexibility. Proton beam therapy is like Gamma knife and LINAC; however, it uses protons or neutrons instead of photons and has been thought to prevent some deleterious side effects related to conventional therapy. In contrast to the concentrated nature of SRS, whole brain radiation therapy (WBRT) is an exposure of the entire cranium to radiation.[87] WBRT is the current standard for treatment of BrMs from NSCLC in patients with multiple metastases.[88] Although WBRT is being replaced with SRS for other forms of BrMs, it remains the standard for NSCLC and SCLC metastases.[89] SRS and WBRT may be used exclusively as well as in con- junction with other modalities.[88] Literature reports that WBRT in addition to SRS has a negative impact on cognitive function post treatment, but also shows lower cancer recurrence rates overall.[85- 87-90-92] Aoyama et al. reported tumor reoccurrence rate of about 45% in SRS + WBRT and about 75% in SRS alone.[86] Brown et al. found that adult patients with 1-3 lung cancer metastasis who underwent SRS+WBRT (n=48) treatment had worse post- operative cognitive scores and neurological deterioration compared to those treated with SRS alone (n=63).[90] These studies suggest that using SRS in conjunction with WBRT could lead to worse cognitive outcomes, but lower rates of tumor recur- rence compared to exclusive SRS treatment.

Treatment via SRS and WBRT differs in dosage and number of fractions. A fraction refers to dividing up the total radiation dosage into multiple treatments and maximizes the effective- ness of radiotherapy. This is accomplished by administering radiation on regularly time intervals which correlate with radiosensitive stages in the cell cycle of cancer cells.[93] SRS treatment typically consists of one fraction at a dose of 15-24 Gray (Gy).[93-95] However, new therapies like hypo-fractioned SRS (HF-SRS), that deliver multiple fractions, have recently shown to increase outcomes and decrease toxici- ty for large (>3cm) tumors.[93] A limitation to this approach is the possibility of tumor cell regrowth between fractioned doses.[93] In contrast to single dose SRS, WBRT is administered in multiple fractions. WBRT irradiates the entire cranium and is typically administered in 10 fractions of 3 Grays (Gy).[84-88-96-97] Literature shows that fraction dosages greater than 3 Gy may be associated with WBRT-related neurotoxic effects.[96-98] WBRT may cause cognitive decline, but it may also treat micro-metastases that have gone undetected on imaging. When ionizing radiation is introduced to tissues, a large quantity of free radicals is created, and these free radicals combined with oxygen in the blood and destroy surround- ing tissues.[99-101] Studies have demonstrated hypoxia to decrease radiation therapy results because of free oxygen able to radicalize.[101,102] As such, hypoxic tumors need 2.5-3 times the radiation dosage to reach the same efficacy as non-hypoxic tumors.[99-103] Fractioning schedules allow time for blood to return to tumor cells, increasing the amount of oxygen available to be ionized and the overall effective- ness of radiotherapy.

Table 2: Summary of comparison between Whole Brain Radiation Therapy (WBRT), and Stereotactic Radiation Surgery (SRS).

Conclusion

The development of brain metastases in lung cancer patients continues to be a major health concern on a global scale. These metastatic tumors significantly increase both morbidity and mortality rates among patients. Despite advances in medical technology, no treatment yet exists without adverse effects, or low remission rates: surgical resection alone leaves concern for untreated micrometases; and radiotherapies are associated with gross cognitive decline. Optimum dosing and fractioning in both stereotactic radio- surgery and whole brain radiation therapy have been investigated to find an optimal approach, but results are not without there drawbacks. Ultimately, the most promising option for improving mortality and morbidity rates lies in the detection of brain metastases as early as possible; thereby minimiz-ng the intensity of treatment and therefore adverse consequences needed

References

1. Cancer Facts & Figures 2021. Published online 1930:72.
   View at Publisher | View at Google Scholar
2. Ferlay, Jacques, Isabelle Soerjomataram, Rajesh Dikshit, Sul- tan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Par- kin, David Forman, and Freddie Bray. "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012." International journal of cancer 136, no. 5 (2015): E359-E386.
   View at Publisher | View at Google Scholar
3. Types of lung cancer | Cancer Research UK. Accessed Au- gust 28, 2022. https://www.cancerresearchuk.org/about- can- cer/lung-cancer/stages-types-grades/types
   View at Publisher | View at Google Scholar
4. Sperduto, Paul W., Norbert Kased, David Roberge, Zhiyuan Xu, Ryan Shanley, Xianghua Luo, Penny K. Sneed et al. "Sum- mary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for pa- tients with brain metastases." Journal of Clinical Oncology 30, no. 4 (2012): 419-425.
   View at Publisher | View at Google Scholar
5. Sacks P, Rahman M. (2020), Epidemiology of Brain Metasta- ses. Neurosurgery Clinics of North America.31(4):481-488.
   View at Publisher | View at Google Scholar
6. Sørensen, J. B., Heine H. Hansen, Mogens Hansen, and P. Dombernowsky. "Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis." Journal of Clinical Oncology 6, no. 9 (1988): 1474-1480.
   View at Publisher | View at Google Scholar
7. Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. "Cancer statistics, 2019." CA: a cancer journal for clinicians 69, no. 1 (2019): 7-34.
   View at Publisher | View at Google Scholar
8. Barnholtz-Sloan, Jill S., Andrew E. Sloan, Faith G. Davis, Fawn D. Vigneau, Ping Lai, and Raymond E. Sawaya. "Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System." Journal of clinical oncology 22, no. 14 (2004): 2865-2872.
   View at Publisher | View at Google Scholar
9. Valastyan, Scott, and Robert A. Weinberg. "Tumor metastasis: molecular insights and evolving paradigms." Cell 147, no. 2 (2011): 275-292.
   View at Publisher | View at Google Scholar
10. Achrol, Achal Singh, Robert C. Rennert, Carey Anders, Riccar- do Soffietti, Manmeet S. Ahluwalia, Lakshmi Nayak, Solange Peters et al. "Brain metastases." Nature Reviews Disease Primers 5, no. 1 (2019): 5.
    View at Publisher | View at Google Scholar
11. Zhao, Ni, Matthew D. Wilkerson, Usman Shah, Xiaoying Yin, Anyou Wang, Michele C. Hayward, Patrick Roberts et al. "Al- terations of LKB1 and KRAS and risk of brain metastasis: com- prehensive characterization by mutation analysis, copy num- ber, and gene expression in non-small-cell lung carcinoma." Lung Cancer 86, no. 2 (2014): 255-261.
    View at Publisher | View at Google Scholar
12. Hayes, D. Neil, Stefano Monti, Giovanni Parmigiani, C. Blake Gilks, Katsuhiko Naoki, Arindam Bhattacharjee, Mark A. So- cinski, Charles Perou, and Matthew Meyerson. "Gene expres- sion profiling reveals reproducible human lung adenocarcino- ma subtypes in multiple independent patient cohorts." Journal of Clinical Oncology 24, no. 31 (2006): 5079-5090.
    View at Publisher | View at Google Scholar
13. Cancer Genome Atlas Research Network. (2014). Compre- hensive molecular profiling of lung adenocarcinoma. Nature, 511(7511), 543.
    View at Publisher | View at Google Scholar
14. Nguyen, Don X., Anne C. Chiang, Xiang H-F. Zhang, Juliet Y. Kim, Mark G. Kris, Marc Ladanyi, William L. Gerald, and Joan Massagué. "WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis." Cell 138, no. 1 (2009): 51-62.
    View at Publisher | View at Google Scholar
15. Ilhan-Mutlu, Aysegül, Christian Siehs, Anna Sophie Berghoff, Gerda Ricken, Georg Widhalm, Ludwig Wagner, and Matthias Preusser. "Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma." Tumor Bi- ology 37 (2016): 1173-1182.
    View at Publisher | View at Google Scholar
16. Fink, Kathleen R., and James R. Fink. "Imaging of brain metas- tases." Surgical neurology international 4, no. Suppl 4 (2013): S209.
    View at Publisher | View at Google Scholar
17. Posner, J. B. "Management of brain metastases." Revue neu- rologique 148, no. 6-7 (1992): 477-487.
    View at Publisher | View at Google Scholar
18. Ali, A., J. R. Goffin, A. Arnold, and P. M. Ellis. "Survival of pa- tients with non-small-cell lung cancer after a diagnosis of brain metastases." Current Oncology 20, no. 4 (2013): e300.
    View at Publisher | View at Google Scholar
19. Sanchez de Cos, Julio, Sojo González, M Victoria Montero, Pérez Calvo, M. J. Vicente, and Manuel Hern ndez Valle. "Non- small cell lung cancer and silent brain metastasis. Survival and prognostic factors." Lung Cancer (Amsterdam, Netherlands) 63, no. 1 (2008): 140-145.
    View at Publisher | View at Google Scholar
20. Bastos, Dhiego Chaves de Almeida, David T. Fuentes, Jeffrey Traylor, Jeffrey Weinberg, Vinodh A. Kumar, Jason Stafford, Jing Li, Ganesh Rao, and Sujit S. Prabhu. "The use of laser in- terstitial thermal therapy in the treatment of brain metastases: a literature review." International Journal of Hyperthermia 37, no. 2 (2020): 53-60.
    View at Publisher | View at Google Scholar
21. Linskey, Mark E., David W. Andrews, Anthony L. Asher, Stuart H. Burri, Douglas Kondziolka, Paula D. Robinson, Mario Am- mirati et al. "The role of stereotactic radiosurgery in the man- agement of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guide- line." Journal of neuro-oncology 96 (2010): 45-68.
    View at Publisher | View at Google Scholar
22. Swinson, Bradley M., and William A. Friedman. "Linear accel- erator stereotactic radiosurgery for metastatic brain tumors: 17 years of experience at the University of Florida." Neurosurgery 62, no. 5 (2008): 1018-1032.
    View at Publisher | View at Google Scholar
23. Chi, Alexander, and Ritsuko Komaki. "Treatment of brain me- tastasis from lung cancer." Cancers 2, no. 4 (2010): 2100-2137.
    View at Publisher | View at Google Scholar
24. Sansur, Charles A., Lawrence S. Chin, John W. Ames, Allen T. Banegura, Sanjeev Aggarwal, Michael Ballesteros, Pradip Amin, J. Marc Simard, and Howard Eisenberg. "Gamma knife radiosurgery for the treatment of brain metastases." Stereotac- tic and functional neurosurgery 74, no. 1 (2000): 37-51.
    View at Publisher | View at Google Scholar
25. Sun, Dian-Shui, Li-Kuan Hu, Ying Cai, Xiao-Mei Li, Lan Ye, Hua-Ying Hou, Cui-Hong Wang, and Yu-Hua Jiang. "A system- atic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer." Asian Pacific Journal of Cancer Prevention 15, no. 3 (2014): 1233-1239.
    View at Publisher | View at Google Scholar
26. An, Ning, Wang Jing, Haoyi Wang, Ji Li, Yang Liu, Jinming Yu, and Hui Zhu. "Risk factors for brain metastases in patients with non–small-cell lung cancer." Cancer medicine 7, no. 12 (2018): 6357-6364.
    View at Publisher | View at Google Scholar
27. Chen, Shanshan, Xin Hua, Jinfang Jia, Ying Wu, Shuzhen Wei, Lu Xu, Shuhua Han, Hongming Zhang, and Xiaoli Zhu. "Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies." (2020).
    View at Publisher | View at Google Scholar
28. Lee, Dong-Soo, Yeon-Sil Kim, So-Lyoung Jung, Kyo-Young Lee, Jin-Hyoung Kang, Sarah Park, Young-Kyoon Kim et al. "The relevance of serum carcinoembryonic antigen as an indi- cator of brain metastasis detection in advanced non-small cell lung cancer." Tumor Biology 33 (2012): 1065-1073.
    View at Publisher | View at Google Scholar
29. Choi, Humberto, Vikram Puvenna, Chanda Brennan, Shamsel- deen Mahmoud, Xiao-Feng Wang, Michael Phillips, Damir Jan- igro, and Peter Mazzone. "S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung can- cer." Translational lung cancer research 5, no. 4 (2016): 413.
    View at Publisher | View at Google Scholar
30. Winther-Larsen, Anne, Claus Vinter Bødker Hviid, Pe- ter Meldgaard, Boe Sandahl Sorensen, and Birgitte Sand- feld-Paulsen. "Neurofilament light chain as a biomarker for brain metastases." Cancers 12, no. 10 (2020): 2852.
    View at Publisher | View at Google Scholar
31. Gaebe, Karolina, Alyssa Y. Li, and Sunit Das. "Clinical biomark- ers for early identification of patients with intracranial metastat- ic disease." Cancers 13, no. 23 (2021): 5973.
    View at Publisher | View at Google Scholar
32. Chen, Lan-tao, Shi-dong Xu, Hai Xu, Jin-feng Zhang, Jin-feng Ning, and Sheng-fa Wang. "MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis." Medical Oncolo- gy 29 (2012): 1673-1680.
    View at Publisher | View at Google Scholar
33. Naresh, Gundu, Prabhat Singh Malik, Sachin Khurana, Deep- am Pushpam, Vinod Sharma, Mukesh Yadav, Deepali Jain, and Sushmita Pathy. "Assessment of brain metastasis at di- agnosis in non–small-cell lung cancer: a prospective observa- tional study from North India." JCO Global Oncology 7 (2021): 593-601.
    View at Publisher | View at Google Scholar
34. Milano, Michael T., James E. Bates, Justin Budnik, Haoming Qiu, Sara Hardy, Michael A. Cummings, Megan A. Baumgart, Ronald J. Maggiore, Deborah A. Mulford, and Kenneth Y. Usuki. "Risk of brain metastases in T1–3N0 NSCLC: a pop- ulation-based analysis." Lung Cancer Management 9, no. 1 (2020): LMT25.
    View at Publisher | View at Google Scholar
35. Ji, Zhe, Nan Bi, Jingbo Wang, Zhouguang Hui, Zefen Xiao, Qinfu Feng, Zongmei Zhou et al. "Risk factors for brain me- tastases in locally advanced non-small cell lung cancer with definitive chest radiation." International Journal of Radiation Oncology* Biology* Physics 89, no. 2 (2014): 330-337.
    View at Publisher | View at Google Scholar
36. Marchi, Nicola, Peter Mazzone, Vincent Fazio, Tarek Mekhail, Thomas Masaryk, and Damir Janigro. "ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients." Cancer: Interdisciplinary International Journal of the American Cancer Society 112, no. 6 (2008): 1313-1324.
    View at Publisher | View at Google Scholar
37. He, Jinlin, Xiaolei Wang, Rensen Xiao, Wei Zuo, Wei Zhang, and Huiming Yao. "Risk factors for brain metastases from non- small-cell lung cancer: a protocol for observational study." Medicine 100, no. 9 (2021): e24724.
    View at Publisher | View at Google Scholar
38. Cheng, Vinton WT, Nicholas de Pennington, Rasheed Zakaria, James R. Larkin, Sébastien Serres, Manjima Sarkar, Matthew A. Kirkman et al. "VCAM-1–targeted MRI improves detection of the tumor-brain interface." Clinical Cancer Research 28, no. 11 (2022): 2385-2396.
    View at Publisher | View at Google Scholar
39. Cheng, Vinton WT, Manuel Sarmiento Soto, Alexandre A. Khrapitchev, Francisco Perez-Balderas, Rasheed Zakaria, Mi- chael D. Jenkinson, Mark R. Middleton, and Nicola R. Sibson. "VCAM-1–targeted MRI enables detection of brain microme- tastases from different primary tumors." Clinical Cancer Re- search 25, no. 2 (2019): 533-543.
    View at Publisher | View at Google Scholar
40. Serres, Sébastien, Manuel Sarmiento Soto, Alastair Hamilton, Martina A. McAteer, W. Shawn Carbonell, Matthew D. Robson, Olaf Ansorge et al. "Molecular MRI enables early and sensitive detection of brain metastases." Proceedings of the National Academy of Sciences 109, no. 17 (2012): 6674-6679.
    View at Publisher | View at Google Scholar
41. Yokoi, Kohei, Noriki Kamiya, Haruhisa Matsuguma, Suguru Machida, Takashi Hirose, Kiyoshi Mori, and Keigo Tominaga. "Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI." Chest 115, no. 3 (1999): 714-719.
    View at Publisher | View at Google Scholar
42. Larkin, James R., Alex M. Dickens, Timothy DW Claridge, Claire Bristow, Kleopatra Andreou, Daniel C. Anthony, and Nicola R. Sibson. "Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice." Theranostics 6, no. 12 (2016): 2161.
    View at Publisher | View at Google Scholar
43. Erickson, Bradley J., Panagiotis Korfiatis, Zeynettin Akkus, and Timothy L. Kline. "Machine learning for medical imaging." ra- diographics 37, no. 2 (2017): 505-515.
    View at Publisher | View at Google Scholar
44. Wagner, Matthias W., Khashayar Namdar, Asthik Biswas, Suranna Monah, Farzad Khalvati, and Birgit B. Ertl-Wagner. "Radiomics, machine learning, and artificial intelligence—what the neuroradiologist needs to know." Neuroradiology (2021): 1-11.
    View at Publisher | View at Google Scholar
45. Cho, Se Jin, Leonard Sunwoo, Sung Hyun Baik, Yun Jung Bae, Byung Se Choi, and Jae Hyoung Kim. "Brain metastasis detection using machine learning: a systematic review and me- ta-analysis." Neuro-oncology 23, no. 2 (2021): 214-225.
    View at Publisher | View at Google Scholar
46. Wang, Kung-Jeng, Bunjira Makond, and Kung-Min Wang. "Modeling and predicting the occurrence of brain metastasis from lung cancer by Bayesian network: a case study of Tai- wan." Computers in biology and medicine 47 (2014): 147-160.
    View at Publisher | View at Google Scholar
47. Zhao, Shuangtao, Jiangyong Yu, and Luhua Wang. "Machine learning based prediction of brain metastasis of patients with IIIA-N2 lung adenocarcinoma by a three-miRNA signature." Translational oncology 11, no. 1 (2018): 157-167.
    View at Publisher | View at Google Scholar
48. Marner, Lisbeth, Otto M. Henriksen, Michael Lundemann, Vibeke Andrée Larsen, and Ian Law. "Clinical PET/MRI in neu- rooncology: opportunities and challenges from a single-institu- tion perspective." Clinical and translational imaging 5 (2017): 135-149.
    View at Publisher | View at Google Scholar
49. Lopci, Egesta, Ciro Franzese, Marco Grimaldi, Paolo Andrea Zucali, Pierina Navarria, Matteo Simonelli, Lorenzo Bello, Mar- ta Scorsetti, and Arturo Chiti. "Imaging biomarkers in primary brain tumours." European journal of nuclear medicine and mo- lecular imaging 42 (2015): 597-612.
    View at Publisher | View at Google Scholar
50. Catana, Ciprian, Alexander Drzezga, Wolf-Dieter Heiss, and Bruce R. Rosen. "PET/MRI for neurologic applications." Jour- nal of nuclear medicine 53, no. 12 (2012): 1916-1925.
    View at Publisher | View at Google Scholar
51. Lohmann, Philipp, Jan-Michael Werner, N. Jon Shah, Gereon R. Fink, Karl-Josef Langen, and Norbert Galldiks. "Combined amino acid positron emission tomography and advanced mag- netic resonance imaging in glioma patients." Cancers 11, no. 2 (2019): 153.
    View at Publisher | View at Google Scholar
52. Mier, Walter, and Daniela Mier. "Advantages in functional im- aging of the brain." Frontiers in human neuroscience 9 (2015): 249.
    View at Publisher | View at Google Scholar
53. Overcast, Wynton B., Korbin M. Davis, Chang Y. Ho, Gary D. Hutchins, Mark A. Green, Brian D. Graner, and Michael C. Veronesi. "Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors." Current Oncology Reports 23 (2021): 1-15.
    View at Publisher | View at Google Scholar
54. Ferda, Jiří, Eva Ferdová, Ondřej Hes, Jan Mraček, Boris Kreuzberg, and Jan Baxa. "PET/MRI: multiparametric imag- ing of brain tumors." European journal of radiology 94 (2017): A14-A25.
    View at Publisher | View at Google Scholar
55. Rosenkrantz, Andrew B., Kent Friedman, Hersh Chandarana, Amy Melsaether, Linda Moy, Yu-Shin Ding, Komal Jhaveri, Luis Beltran, and Rajan Jain. "Current status of hybrid PET/MRI in oncologic imaging." American journal of roentgenology 206, no. 1 (2016): 162-172.
    View at Publisher | View at Google Scholar
56. Heiss, Wolf-Dieter. "The potential of PET/MR for brain imag- ing." European journal of nuclear medicine and molecular im- aging 36 (2009): 105-112.
    View at Publisher | View at Google Scholar
57. Rausch, Ivo, Lucas Rischka, Claes N. Ladefoged, Julia Furt- ner, Matthias Fenchel, Andreas Hahn, Rupert Lanzenberger, Marius E. Mayerhoefer, Tatjana Traub-Weidinger, and Thomas Beyer. "PET/MRI for oncologic brain imaging: a comparison of standard MR-based attenuation corrections with a mod- el-based approach for the Siemens mMR PET/MR system." Journal of Nuclear Medicine 58, no. 9 (2017): 1519-1525.
    View at Publisher | View at Google Scholar
58. Mayerhoefer, Marius E., Helmut Prosch, Lucian Beer, Dietmar Tamandl, Thomas Beyer, Christoph Hoeller, Dominik Berzaczy et al. "PET/MRI versus PET/CT in oncology: a prospective sin- gle-center study of 330 examinations focusing on implications for patient management and cost considerations." European journal of nuclear medicine and molecular imaging 47 (2020): 51-60.
    View at Publisher | View at Google Scholar
59. Puttick, Simon, Christopher Bell, Nicholas Dowson, Stephen Rose, and Michael Fay. "PET, MRI, and simultaneous PET/ MRI in the development of diagnostic and therapeutic strate- gies for glioma." Drug discovery today 20, no. 3 (2015): 306- 317.
    View at Publisher | View at Google Scholar
60. Quartuccio, Natale, Riccardo Laudicella, Antonio Vento, Sal- vatore Pignata, Maria Vittoria Mattoli, Rossella Filice, Alessio Danilo Comis et al. "The additional value of 18F-FDG PET and MRI in patients with glioma: a review of the literature from 2015 to 2020." Diagnostics 10, no. 6 (2020): 357.
    View at Publisher | View at Google Scholar
61. Verberne, S. J., and O. P. P. Temmerman. "Imaging of pros- thetic joint infections." In Management of periprosthetic joint infections (PJIs), pp. 259-285. Woodhead Publishing, 2017.
    View at Publisher | View at Google Scholar
62. Nandu, Hari, Patrick Y. Wen, and Raymond Y. Huang. "Imaging in neuro-oncology." Therapeutic advances in neurological dis- orders 11 (2018): 1756286418759865.
    View at Publisher | View at Google Scholar
63. Glaudemans, Andor WJM, Roelien H. Enting, Mart AAM Heesters, Rudi AJO Dierckx, Ronald WJ van Rheenen, Annemiek ME Walenkamp, and Riemer HJA Slart. "Value of 11 C-methionine PET in imaging brain tumours and metastases." European journal of nuclear medicine and molecular imaging 40 (2013): 615-635.
    View at Publisher | View at Google Scholar
64. Mehta, Minesh P., Patrick Rodrigus, C. H. J. Terhaard, Aroor Rao, John Suh, Wilson Roa, Luis Souhami et al. "Survival and neurologic outcomes in a randomized trial of motexafin gado- linium and whole-brain radiation therapy in brain metastases." Journal of Clinical Oncology 21, no. 13 (2003): 2529-2536.
    View at Publisher | View at Google Scholar
65. Temel, Jennifer S., Joseph A. Greer, Alona Muzikansky, Emily R. Gallagher, Sonal Admane, Vicki A. Jackson, Constance M. Dahlin et al. "Early palliative care for patients with metastatic non–small-cell lung cancer." New England Journal of Medicine 363, no. 8 (2010): 733-742.
    View at Publisher | View at Google Scholar
66. Langer, Corey J., and Minesh P. Mehta. "Current management of brain metastases, with a focus on systemic options." Journal of clinical oncology 23, no. 25 (2005): 6207-6219.
    View at Publisher | View at Google Scholar
67. Ruderman, Neil B., and Thomas C. Hall. "Use of glucocorti- coids in the palliative treatment of metastatic brain tumors." Cancer 18, no. 3 (1965): 298-306.
    View at Publisher | View at Google Scholar
68. Khuntia, Deepak, Paul Brown, Jing Li, and Minesh P. Mehta. "Whole-brain radiotherapy in the management of brain me- tastasis." Journal of Clinical Oncology 24, no. 8 (2006): 1295- 1304.
    View at Publisher | View at Google Scholar
69. Kotecha, Rupesh, Vinai Gondi, Manmeet S. Ahluwalia, Pris- cilla K. Brastianos, and Minesh P. Mehta. "Recent advances in managing brain metastasis." F1000Research 7 (2018): F1000-Faculty.
    View at Publisher | View at Google Scholar
70. Hatiboglu, Mustafa Aziz, Kerime Akdur, and Raymond Sawaya. "Neurosurgical management of patients with brain metastasis." Neurosurgical review 43, no. 2 (2020): 483-495.
    View at Publisher | View at Google Scholar
71. Bruzzaniti, Placido, Pierfrancesco Lapolla, A. L. E. S. S. I. A. D’AMICO, Giuseppa Zancana, Michael Katsev, Michela Relu- centi, Giuseppe Familiari et al. "En bloc resection of solitary brain metastasis: the role of perilesional edema." in vivo 36, no. 3 (2022): 1274-1284.
    View at Publisher | View at Google Scholar
72. Wen, Patrick Y., and Jay S. Loeffler. "Brain metastases." Cur- rent treatment options in oncology 1 (2000): 447-457.
    View at Publisher | View at Google Scholar
73. Esquenazi, Yoshua, Victor P. Lo, and Kiwon Lee. "Critical care management of cerebral edema in brain tumors." Journal of intensive care medicine 32, no. 1 (2017): 15-24.
    View at Publisher | View at Google Scholar
74. Baris, Mustafa Mahmut, Ahmet Orhan Celik, Naciye Sinem Gezer, and Emel Ada. "Role of mass effect, tumor volume and peritumoral edema volume in the differential diagnosis of pri- mary brain tumor and metastasis." Clinical neurology and neu- rosurgery 148 (2016): 67-71.
    View at Publisher | View at Google Scholar
75. Bilgin, E. Yaltirik, Ozkan Unal, and Nazan Ciledag. "Vasogenic Edema Pattern in Brain Metastasis." Age 60, no. 149 (2022): 51.
    View at Publisher | View at Google Scholar
76. Kalkanis, Steven N., Douglas Kondziolka, Laurie E. Gaspar, Stuart H. Burri, Anthony L. Asher, Charles S. Cobbs, Mario Am- mirati et al. "The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline." Journal of neu- ro-oncology 96 (2010): 33-43.
    View at Publisher | View at Google Scholar
77. Nemeth, A. J., J. W. Henson, M. E. Mullins, R. G. Gonzalez, and Pamela W. Schaefer. "Improved detection of skull metas- tasis with diffusion-weighted MR imaging." American journal of neuroradiology 28, no. 6 (2007): 1088-1092.
    View at Publisher | View at Google Scholar
78. Tirinato, Luca, Valentina Onesto, Daniel Garcia-Calderon, Francesca Pagliari, Maria-Francesca Spadea, Joao Seco, and Francesco Gentile. "Human lung-cancer-cell radioresistance investigated through 2D network topology." Scientific reports 12, no. 1 (2022): 12980.
    View at Publisher | View at Google Scholar
79. Yao, Yongfang, Rameesha Fareed, Aliya Zafar, Kalsoom Sal- eem, Tao Huang, Yongtao Duan, and Masood Ur Rehman. "State-of-the-art combination treatment strategies for ad- vanced stage non–small cell lung cancer." Frontiers in Oncolo- gy 12 (2022): 958505.
    View at Publisher | View at Google Scholar
80. Ozcan, Gonca, Meghana Singh, and James J. Vredenburgh. "Leptomeningeal metastasis from non–small cell lung cancer and current landscape of treatments." Clinical Cancer Re- search 29, no. 1 (2023): 11-29.
    View at Publisher | View at Google Scholar
81. Park, Sue Jee, Sa-Hoe Lim, Young-Jin Kim, Kyung-Sub Moon, In-Young Kim, Shin Jung, Seul-Kee Kim, In-Jae Oh, Jong- Hwan Hong, and Tae-Young Jung. "The tumor control accord- ing to radiation dose of gamma knife radiosurgery for small and medium-sized brain metastases from non-small cell lung can- cer." Journal of Korean Neurosurgical Society 64, no. 6 (2021): 983-994.
    View at Publisher | View at Google Scholar
82. Devan, Sean P., Xiaoyu Jiang, Guozhen Luo, Jingping Xie, James D. Quirk, John A. Engelbach, Hannah Harmsen et al. "Selective cell size MRI differentiates brain tumors from radia- tion necrosis." Cancer research 82, no. 19 (2022): 3603-3613.
    View at Publisher | View at Google Scholar
83. Paek, Sun Ha, Paul B. Audu, Michael R. Sperling, Joon Cho, and David W. Andrews. "Reevaluation of surgery for the treat- ment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with mod- ern neurosurgical techniques." Neurosurgery 56, no. 5 (2005): 1021-1034.
    View at Publisher | View at Google Scholar
84. Desai, Rupen, and Keith M. Rich. "Therapeutic role of gamma knife stereotactic radiosurgery in neuro-oncology." Missouri medicine 117, no. 1 (2020): 33.
    View at Publisher | View at Google Scholar
85. Goldberg, Sarah B., Joseph N. Contessa, Sacit B. Omay, and Veronica Chiang. "Lung cancer brain metastases." The Cancer Journal 21, no. 5 (2015): 398-403.
    View at Publisher | View at Google Scholar
86. Abe, Eisuke, and Hidefumi Aoyama. "The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery." Current oncology reports 14 (2012): 79-84.
    View at Publisher | View at Google Scholar
87. Perlow, Haley K., Khaled Dibs, Kevin Liu, William Jiang, Pra- jwal Rajappa, Dukagjin M. Blakaj, Joshua Palmer, and Raju R. Raval. "Whole-brain radiation therapy versus stereotactic ra- diosurgery for cerebral metastases." Neurosurgery Clinics 31, no. 4 (2020): 565-573.
    View at Publisher | View at Google Scholar
88. Sas-Korczynska, Beata, and Monika Rucinska. "WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view." Journal of Thoracic Disease 13, no. 5 (2021): 3246.
    View at Publisher | View at Google Scholar
89. Rusthoven, Chad G., Masaaki Yamamoto, Denise Bernhardt, Derek E. Smith, Dexiang Gao, Toru Serizawa, Shoji Yomo et al. "Evaluation of first-line radiosurgery vs whole-brain radiothera- py for small cell lung cancer brain metastases: the FIRE-SCLC cohort study." JAMA oncology 6, no. 7 (2020): 1028-1037.
    View at Publisher | View at Google Scholar
90. Brown, Paul D., Kurt Jaeckle, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero et al. "Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial." Jama 316, no. 4 (2016): 401-409.
    View at Publisher | View at Google Scholar
91. Tallet, Agnes V., David Azria, Fabrice Barlesi, Jean-Philippe Spano, Antoine F. Carpentier, Antony Gonçalves, and Philippe Metellus. "Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment." Radiation Oncology 7 (2012): 1-8.
    View at Publisher | View at Google Scholar
92. Lee, Jiyun, and Myung-Ju Ahn. "Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy." Cancer Treatment Reviews 100 (2021): 102291.
    View at Publisher | View at Google Scholar
93. Kirkpatrick, John P., Scott G. Soltys, Simon S. Lo, Kathryn Beal, Dennis C. Shrieve, and Paul D. Brown. "The radiosurgery fractionation quandary: single fraction or hypofractionation?." Neuro-oncology 19, no. suppl_2 (2017): ii38-ii49.
    View at Publisher | View at Google Scholar
94. Badiyan, Shahed N., William F. Regine, and Minesh Mehta. "Stereotactic radiosurgery for treatment of brain metastases." Journal of oncology practice 12, no. 8 (2016): 703-712
    View at Publisher | View at Google Scholar
95. Gondi, Vinai, Glenn Bauman, Lisa Bradfield, Stuart H. Burri, Alvin R. Cabrera, Danielle A. Cunningham, Bree R. Eaton et al. "Radiation therapy for brain metastases: an ASTRO clini- cal practice guideline." Practical radiation oncology 12, no. 4 (2022): 265-282.
    View at Publisher | View at Google Scholar
96. Rades, Dirk, Tiina Haatanen, Steven E. Schild, and Juergen Dunst. "Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases." Cancer 110, no. 6 (2007): 1345-1350.
    View at Publisher | View at Google Scholar
97. Trifiletti, Daniel M., Karla V. Ballman, Paul D. Brown, S. Keith Anderson, Xiomara W. Carrero, Jane H. Cerhan, Anthony C. Whitton et al. "Optimizing whole brain radiation therapy dose and fractionation: Results from a prospective phase 3 trial (NCCTG N107C [Alliance]/CEC. 3)." International Journal of Radiation Oncology* Biology* Physics 106, no. 2 (2020): 255- 260.
    View at Publisher | View at Google Scholar
98. Jairam, Vikram, Veronica L. Chiang, James Bond, and James B. Yu. "Equivalent whole brain dose for patients undergoing gamma knife for multiple lesions." Journal of Radiosurgery and SBRT 3, no. 3 (2015): 187.
    View at Publisher | View at Google Scholar
99. Sørensen, Brita Singers, and Michael R. Horsman. "Tumor hy- poxia: impact on radiation therapy and molecular pathways." Frontiers in oncology 10 (2020): 562..
    View at Publisher | View at Google Scholar
100. Horsman, Michael R., Lise Saksø Mortensen, Jørgen B. Pe- tersen, Morten Busk, and Jens Overgaard. "Imaging hypoxia to improve radiotherapy outcome." Nature reviews Clinical on- cology 9, no. 12 (2012): 674-687.
     View at Publisher | View at Google Scholar
101. Overgaard, Jens. "Hypoxic radiosensitization: adored and ig- nored." Journal of Clinical Oncology 25, no. 26 (2007): 4066- 4074.
     View at Publisher | View at Google Scholar
102. Yoshimura, Michio, Satoshi Itasaka, Hiroshi Harada, and Ma- sahiro Hiraoka. "Microenvironment and radiation therapy." BioMed research international 2013, no. 1 (2013): 685308.
     View at Publisher | View at Google Scholar
103. Gray, Louis Harold, A_D Conger, Michael Ebert, S. Hornsey, and O. C. A. Scott. "The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy." The British journal of radiology 26, no. 312 (1953): 638-648.
     View at Publisher | View at Google Scholar